Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer-Reference-Cited by-同舟云学术

Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer

Published:2019-05-31 Issue:1 Volume:146 Page:123-136
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Raninga Prahlad V.¹,Lee Andy C.²,Sinha Debottam¹,Shih Yu‐Yin³,Mittal Deepak¹,Makhale Ashwini¹,Bain Amanda L.¹,Nanayakarra Devathri¹,Tonissen Kathryn F.⁴⁵,Kalimutho Murugan¹,Khanna Kum Kum¹^ORCID

Affiliation:

1. QIMR Berghofer Medical Research Institute Brisbane QLD Australia

2. Radiation Biology Research Center, Institute for Radiological Research, Chang Gung Memorial Hospital/Chang Gung University Taoyuan Taiwan

3. Research Center for Emerging Viral Infection, Chang Gung University Taoyuan Taiwan

4. School of Environment and Science, Griffith University, Brisbane QLD Australia

5. Griffith Research Institute for Drug Discovery, Griffith University Brisbane QLD Australia

Funder

National Breast Cancer Foundation

National Health and Medical Research Council

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32410

Reference47 articles.

1. Oxidants and Antioxidants in Breast Cancer

2. THIOREDOXIN

3. The changing faces of glutathione, a cellular protagonist

4. Role of Glutathione in Cancer Progression and Chemoresistance

5. Glutathione and Glutaredoxin Act as a Backup of Human Thioredoxin Reductase 1 to Reduce Thioredoxin 1 Preventing Cell Death by Aurothioglucose

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The rheumatoid arthritis drug auranofin exerts potent anti-lymphoma effect by stimulating TXNRD-mediated ROS generation and inhibition of energy metabolism;Redox Biology;2024-09

2. Metabolic and Oxidative Stress Management Heterogeneity in a Panel of Breast Cancer Cell Lines;Metabolites;2024-08-06

3. Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides—Current Developments in Structure-Activity Relationship;International Journal of Molecular Sciences;2024-07-03

4. The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity;Nature Communications;2024-05-31

5. Antioxidant Enzymes and Their Potential Use in Breast Cancer Treatment;International Journal of Molecular Sciences;2024-05-23